Aligos Therapeutics, Inc. (ALGS)
| Market Cap | 1.25B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -73.06M |
| Shares Out | 36.89M |
| EPS (ttm) | -1.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $30.41 |
| Previous Close | $32.85 |
| Change ($) | -2.45 |
| Change (%) | -7.44% |
| Day's Open | 33.50 |
| Day's Range | 29.47 - 33.91 |
| Day's Volume | 28,152 |
| 52-Week Range | 13.20 - 34.94 |
Aligos (ALGS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to ...
SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing no...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to ...
Nine IPOs and five SPACs went public this past week, and one IPO postponed.
Shares of Aligos Therapeutics Inc. rallied out of the gate Friday, as they opened 16% above the initial public offering price. The stock's first trade on the Nasdaq was at $17.40 at 1:33 p.m.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its initial public offering of 10,000,000 shares of its c...
About ALGS
Aligos Therapeutics, a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-ß agonist for the treatm... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2020 |
| CEO Dr. Lawrence M. Blatt | Employees 73 |
| Stock Exchange NASDAQ | Ticker Symbol ALGS |
Analyst Forecasts
According to 4 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is 34.50, which is an increase of 13.47% from the latest price.